期刊文献+

慢性淋巴细胞白血病合并全身多发骨质破坏一例并文献复习 被引量:2

Chronic lymphocytic leukemia complicated with multiple bones destruction: report of one case and review of literature
原文传递
导出
摘要 目的探讨慢性淋巴细胞白血病(CLL)合并全身多发骨质破坏患者的临床特征。方法分析1例合并全身多发骨质破坏CLL患者的临床及实验室资料,并复习相关文献。结果与出现Ritcher转化或二重肿瘤后所致的溶骨性损害不同,CLL患者骨质破坏部位集中于颌面骨、颅骨、胸腰椎、肋骨等人体中轴骨。该例患者疾病侵袭性强、进展快,病程中伴有高钙血症,接受利妥昔单抗+氟达拉滨+环磷酰胺(R-FC)方案以及CD52单克隆抗体等治疗均不能获得完全缓解。结论合并全身多发骨质破坏的CLL患者较为罕见,其骨质破坏部位多位于人体中轴骨,且具有疾病恶性程度高、常规化疗效果差等不良预后的临床特征。
作者 孙京男 靳凤艳 李薇 Liu Xuelian Sun Jingnan Jin Fengyan Li Wei(Department of Hematology, Cancer Center, the First Bethune Hospital of Jilin University, Changehun 130021, China)
出处 《白血病.淋巴瘤》 CAS 2017年第9期556-559,共4页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献1

二级参考文献32

  • 1Lundin J, Kimby E, Bjorkbolm M, et al.Phase 1I trial of subcutaneous anti - CD52monoclonal antibody alemtuzumab (CAMPATH- IH)as lust-line treatment for patients with B- cell chronic lymphocytic leukemia(B - CLL) [J]. Blood ,2002,100:768 -773.
  • 2Byrd J C, Peterson B L, Morrison V A, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic,untreated patients with B- cell chronic lymphocytic leukemia:Results from Cancer and Leukemia Gr
  • 3Widrda W, O'Brien S, Albitar M, et al.Combined fludarabine, cyclophosphamide,and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukaemia[J]. Blood,2001,98(suppl 1):771a.
  • 4Garcia-Manero G, O'Brien S, Cortes J, et al. Update of the results of the combination of fludarabine, cyelophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL)[J].Blood ,2001,98(suppl 1):663a.
  • 5Dreger P, Brand R, Hansz J, et al. Treatment- related mortality and graft- versusleukemia activity after allogeneie stem cell transplantation for chronic lymphocytic leukemia using intensity- reduced conditioning[J]. Leukemia, 2003,17:841-848.
  • 6Jaksic B, Brugiatelli M, Ivo K, et al. High dose chlorambucil versus Binet's modified cyclophosphamide,doxorubicin,vincristine,and prednisene regimen in the treatment of patients with advanced B- cell chronic lymphocytc leukemia results of an internationa
  • 7Sorensen J M, Vena D A, Fallavollita A, et al. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute:five - year follow-up report[J]. J Clin Oncol,1997,15:458 -4
  • 8Rat K R, Byrd J C, Peterson B, et al. A phase Ⅱ trial of fludarabine followed by alemtuzumab (CAMPATH- IH)in previously untreated chronic lymphocytic leukemia(CLL)patients with active disease:Cancer and Leukemia Group B (CALGB)Study 19901[J]. Blood,2002,
  • 9Leporrier M, Chevret S, Cazin B, et al.Randomized comparison of fludarahine,CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic Ieukemia patients [J]. Blood,2001,98(8):2319-2325.
  • 10Kalil N,Cheson B D. Chronic lymphocytic leukemia[J]. The Oncologist, 1999,4:352-356.

共引文献1

同被引文献21

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部